{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:20:05Z","timestamp":1793262005571,"version":"4.5.0"},"reference-count":44,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2019-0250_s_999_w2aab3b7b5b1b6b1aab1c16b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of lipid-lowering treatment in children with heterozygous familial hypercholesterolemia (HeFH) aged \u226412 years attending a tertiary hospital-based outpatient lipid clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2019-0250_s_998_w2aab3b7b5b1b6b1aab1c16b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data in 318 children from the University Hospital of Ioannina (Northwestern Greece) Outpatient Lipid Clinic Project for Children and Adolescents with Dyslipidemia from March 2009 to December 2018 were analyzed. We assessed the efficacy and safety treatment alongside any possible predictors of the achievement of the treatment target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2019-0250_s_997_w2aab3b7b5b1b6b1aab1c16b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 318 children with hyperlipidemia, 72 were diagnosed having HeFH based on clinical criteria and genetic confirmation. Compared with non-familial hypercholesterolemia (non-FH) children, those with FH had a higher occurrence of positive family history of premature cardiovascular disease, and higher levels of total, low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB) and lipoprotein (a) (Lp(a)). Treatment regimens included either atorvastatin 10\u201320 mg\/day, rosuvastatin 5\u201310 mg\/day, pitavastatin 2\u20134 mg\/day monotherapy or in combination with ezetimibe. The treatment goal of LDL-C (&lt;135 mg\/dL, 3.5 mmol\/L) was achieved in 69% of children treated. The achievement of the treatment targets correlated positively with male sex and inversely with the Dutch Lipid Clinic Network Score, baseline total, LDL-C and apoB levels. No clinically significant changes in liver or muscle-related laboratory tests were reported; no effect on growth or sexual maturation was noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2019-0250_s_996_w2aab3b7b5b1b6b1aab1c16b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study confirms that lipid-lowering treatment in HeFH children initiated in the setting of a specialized tertiary hospital-based outpatient lipid clinic is efficacious and safe. Children of male sex and low baseline lipid values had a better achievement of treatment target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2019-0250","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T04:02:06Z","timestamp":1582257726000},"page":"533-538","source":"Crossref","is-referenced-by-count":13,"title":["Nine-year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia: a university hospital outpatient lipid clinic project in Northwestern Greece"],"prefix":"10.1515","volume":"33","author":[{"given":"Thomas","family":"Benekos","sequence":"first","affiliation":[{"name":"Outpatient Lipid Clinic for Children and Adolescents of the University Hospital of Ioannina, University of Ioannina, Ioannina, Greece"},{"name":"Child Health Department, University of Ioannina, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Kosmeri","sequence":"additional","affiliation":[{"name":"Outpatient Lipid Clinic for Children and Adolescents of the University Hospital of Ioannina, University of Ioannina, Ioannina, Greece"},{"name":"Child Health Department, University of Ioannina, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Vlahos","sequence":"additional","affiliation":[{"name":"Outpatient Lipid Clinic for Children and Adolescents of the University Hospital of Ioannina, University of Ioannina, Ioannina, Greece"},{"name":"Child Health Department, University of Ioannina, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos","family":"Milionis","sequence":"additional","affiliation":[{"name":"Outpatient Lipid Clinic for Children and Adolescents of the University Hospital of Ioannina, University of Ioannina, Ioannina, Greece"},{"name":"Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref241","first-page":"482","article-title":"Familial hypercholesterolemia \u2013 epidemiology, diagnosis, and screening","volume":"17","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.atherosclerosis.2014.09.031","article-title":"Familial Hypercholesterolemia in Greek children and their families: genotype-to-phenotype correlations and a reconsideration of LDLR mutation spectrum","volume":"237","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1210\/jc.2007-0275","article-title":"Update on dyslipidemia","volume":"92","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref421","first-page":"1023","article-title":"Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia","volume":"6","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/humu.1121","article-title":"Characterization and geographic distribution of the low density lipoprotein receptor (LDLR) gene mutations in northwestern Greece","volume":"17","year":"2001","journal-title":"Hum Mut"},{"key":"ref231","first-page":"53","article-title":"The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations","volume":"3","year":"2010","journal-title":"Appl Clin Genet"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-3476(98)70174-X","article-title":"Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy","volume":"133","year":"1998","journal-title":"J Pediatr"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year follow-up of statins in children with familial hypercholesterolemia","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial","volume":"292","year":"2004","journal-title":"J Am Med Assoc"},{"key":"ref21","first-page":"482","article-title":"Familial hypercholesterolemia \u2013 epidemiology, diagnosis, and screening","volume":"17","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacl.2015.07.011","article-title":"Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study","volume":"9","year":"2015","journal-title":"J Clin Lipidol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial","volume":"292","year":"2004","journal-title":"J Am Med Assoc"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/humu.1121","article-title":"Characterization and geographic distribution of the low density lipoprotein receptor (LDLR) gene mutations in northwestern Greece","volume":"17","year":"2001","journal-title":"Hum Mut"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacl.2015.07.011","article-title":"Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study","volume":"9","year":"2015","journal-title":"J Clin Lipidol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1542\/peds.2008-1349","article-title":"Lipid screening and cardiovascular health in childhood","volume":"122","year":"2008","journal-title":"Pediatrics"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-3476(98)70174-X","article-title":"Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy","volume":"133","year":"1998","journal-title":"J Pediatr"},{"key":"ref131","first-page":"Cd006401","article-title":"Statins for children with familial hypercholesterolemia","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jpeds.2015.02.043","article-title":"Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia","volume":"166","year":"2015","journal-title":"J Pediatr"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jamapediatrics.2014.3216","article-title":"Prevalence of and trends in dyslipidemia and blood pressure among US children and adolescents, 1999\u20132012","volume":"169","year":"2015","journal-title":"JAMA Pediatr"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"ref201","first-page":"1023","article-title":"Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia","volume":"6","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpeds.2016.08.003","article-title":"Correlates of achieving statin therapy goals in children and adolescents with dyslipidemia","volume":"178","year":"2016","journal-title":"J Pediatr"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jpeds.2015.02.043","article-title":"Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia","volume":"166","year":"2015","journal-title":"J Pediatr"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jacl.2014.12.003","article-title":"Gender-related lipid and\/or lipoprotein responses to statins in subjects in primary and secondary prevention","volume":"9","year":"2015","journal-title":"J Clin Lipidol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/01.CIR.0000035247.42888.82","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1542\/peds.2008-1349","article-title":"Lipid screening and cardiovascular health in childhood","volume":"122","year":"2008","journal-title":"Pediatrics"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","year":"2011","journal-title":"Eur Heart J"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpeds.2016.08.003","article-title":"Correlates of achieving statin therapy goals in children and adolescents with dyslipidemia","volume":"178","year":"2016","journal-title":"J Pediatr"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/01.CIR.0000035247.42888.82","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","year":"2011","journal-title":"Eur Heart J"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1210\/jc.2007-0275","article-title":"Update on dyslipidemia","volume":"92","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jamapediatrics.2014.3216","article-title":"Prevalence of and trends in dyslipidemia and blood pressure among US children and adolescents, 1999\u20132012","volume":"169","year":"2015","journal-title":"JAMA Pediatr"},{"key":"ref11","first-page":"53","article-title":"The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations","volume":"3","year":"2010","journal-title":"Appl Clin Genet"},{"key":"ref351","first-page":"Cd006401","article-title":"Statins for children with familial hypercholesterolemia","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jacl.2014.12.003","article-title":"Gender-related lipid and\/or lipoprotein responses to statins in subjects in primary and secondary prevention","volume":"9","year":"2015","journal-title":"J Clin Lipidol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year follow-up of statins in children with familial hypercholesterolemia","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00246-013-0742-0","article-title":"Endothelial dysfunction, but not structural atherosclerosis, is evident early in children with heterozygous familial hypercholesterolemia","volume":"35","year":"2014","journal-title":"Pediatr Cardiol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00246-013-0742-0","article-title":"Endothelial dysfunction, but not structural atherosclerosis, is evident early in children with heterozygous familial hypercholesterolemia","volume":"35","year":"2014","journal-title":"Pediatr Cardiol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.atherosclerosis.2014.09.031","article-title":"Familial Hypercholesterolemia in Greek children and their families: genotype-to-phenotype correlations and a reconsideration of LDLR mutation spectrum","volume":"237","year":"2014","journal-title":"Atherosclerosis"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/jpem\/33\/4\/article-p533.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2019-0250\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T21:46:15Z","timestamp":1619041575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2019-0250\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":44,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1515\/jpem-2019-0250","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,28]]}}}